The 21-gene Recurrence Score® assay predicts distant recurrence in lymph node-positive, hormone receptor-positive, breast cancer patients treated with adjuvant sequential epirubicin- and docetaxel-based or epirubicin-based chemotherapy (PACS-01 trial)

The 21-gene Recurrence Score® assay predicts distant recurrence in lymph node-positive, hormone receptor-positive, breast cancer patients treated with adjuvant sequential epirubicin- and docetaxel-based or epirubicin-based chemotherapy (PACS-01 trial)

Abstract Background The 21-gene Recurrence Score (RS) result predicts outcome and chemotherapy benefit in node-negative and node-positive (N+), estrogen receptor-positive (ER+) patients treated with endocrine therapy. The purpose of this study was to evaluate the prognostic impact of RS results in N...

Full description

Bibliographic Details
Main Authors: Frédérique Penault-Llorca, Thomas Filleron, Bernard Asselain, Frederick L. Baehner, Pierre Fumoleau, Magali Lacroix-Triki, Joseph M. Anderson, Carl Yoshizawa, Diana B. Cherbavaz, Steven Shak, Lise Roca, Christine Sagan, Jérôme Lemonnier, Anne-Laure Martin, Henri Roché
Format: Article
Language:English
Published: BMC 2018-05-01
Series:BMC Cancer
Subjects:
Adjuvant chemotherapy
Breast cancer
Docetaxel
Epirubicin
Hormone receptor-positive
Lymph node-positive
Online Access:http://link.springer.com/article/10.1186/s12885-018-4331-8

Internet

http://link.springer.com/article/10.1186/s12885-018-4331-8

Similar Items